Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.

Chung LY, Kang E, Nam HK, Rhie YJ, Lee KH

Journal of Korean medical science30 Aug 2021Cited by 21 (Europe PMC)

PMID34463062PMCIDPMC8405405DOI10.3346/jkms.2021.36.e219PepBankPUB-34463062

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with central precocious puberty, LH suppression rates did not differ significantly between triptorelin 3-month and 1-month depots at 6 months.
In plain wordsIn girls with early puberty, LH suppression rates did not differ significantly between triptorelin 3-month and 1-month depots at 6 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLH suppression at 6 months
Study
n = 106
Comparator
triptorelin 3.75 mg 1-month depot
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
LH suppression rate
90%
3-month depot
LH suppression rate
98.2%
1-month depot
Source sentences
Summary
A suppressed levels of LH to the triptorelin injection (serum LH P = 0.160).
3 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to compare the efficacy of a triptorelin 11.25 mg 3-month depot with that of a 3.75 mg 1-month depot in suppressing pubertal development for the treatment of CPP.
Summary · context
A retrospective study, including 106 girls with CPP treated with triptorelin, was conducted.
Summary · context
Fifty patients were treated with a triptorelin 3-month depot, and 56 were treated with a triptorelin 1-month depot.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3446306201
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with central precocious puberty, LH suppression rates did not differ significantly between triptorelin 3-month and 1-month depots after 1 year.
In plain wordsIn girls with early puberty, LH suppression rates did not differ significantly between triptorelin 3-month and 1-month depots after 1 year.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLH suppression at 1 year
Study
n: not reported in source
Comparator
triptorelin 3.75 mg 1-month depot
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
LH suppression rate
93.5%
3-month depot
LH suppression rate
100%
1-month depot
Source sentences
Summary
After 1 year of treatment, a suppressed levels of LH was seen in 93.5% and 100% of the girls treated with the 3-month and 1-month depots, respectively (P = 0.226).
3 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to compare the efficacy of a triptorelin 11.25 mg 3-month depot with that of a 3.75 mg 1-month depot in suppressing pubertal development for the treatment of CPP.
Summary · context
A retrospective study, including 106 girls with CPP treated with triptorelin, was conducted.
Summary · context
Fifty patients were treated with a triptorelin 3-month depot, and 56 were treated with a triptorelin 1-month depot.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3446306202
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with central precocious puberty, height velocity did not differ significantly between triptorelin 3-month and 1-month depots.
In plain wordsIn girls with early puberty, height growth did not differ significantly between triptorelin 3-month and 1-month depots.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeHeight velocity
Study
n: not reported in source
Comparator
triptorelin 3.75 mg 1-month depot
Outcome group
Linear growth · Endocrine and hormones
Source sentences
Summary
Height velocity showed no significant difference between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to compare the efficacy of a triptorelin 11.25 mg 3-month depot with that of a 3.75 mg 1-month depot in suppressing pubertal development for the treatment of CPP.
Summary · context
A retrospective study, including 106 girls with CPP treated with triptorelin, was conducted.
Summary · context
Fifty patients were treated with a triptorelin 3-month depot, and 56 were treated with a triptorelin 1-month depot.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3446306203
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with central precocious puberty, bone age advancement declined in both depot groups, without a significant between-group difference after 1 year.
In plain wordsIn girls with early puberty, bone age advancement declined similarly with triptorelin 3-month and 1-month depots after 1 year.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBone age advancement
Study
n: not reported in source
Comparator
triptorelin 3.75 mg 1-month depot
Outcome group
Bone and joint · Endocrine and hormones
Measurements
Bone age advancement
1.22 years
3-month depot, baseline
Bone age advancement
1.22 years
1-month depot, baseline
Bone age advancement
1.16 years
3-month depot, after 1 year
Bone age advancement
1.17 years
1-month depot, after 1 year
Source sentences
Summary
Degree of bone age advancement decreased from 1.22 ± 0.07 and 1.22 ± 0.08 years at baseline (P = 0.914) to 1.16 ± 0.07 and 1.17 ± 0.08 in the girls treated with the 3-month and 1-month depots after 1 year, respectively (P = 0.481).
3 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to compare the efficacy of a triptorelin 11.25 mg 3-month depot with that of a 3.75 mg 1-month depot in suppressing pubertal development for the treatment of CPP.
Summary · context
A retrospective study, including 106 girls with CPP treated with triptorelin, was conducted.
Summary · context
Fifty patients were treated with a triptorelin 3-month depot, and 56 were treated with a triptorelin 1-month depot.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3446306204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT06487143

Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universityn = 134est. 1 Jul 2024 to est. 30 Dec 2026

Central Precocious Puberty

Trial page ClinicalTrials.govUpdated 5 Jul 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.